Affiris begins clinical testing of Alzheimer's vaccine

[Guest guest]

http://www.pharmaceutical-business-review.com/article_news.asp?guid=CB01C8CF

-CB0A-4835-99F2-C8FE5EB25286

Affiris begins clinical testing of Alzheimer's vaccine

20th July 2007

By Staff Writer

Affiris' Alzheimer's vaccine Affitope has now entered the clinical phase of

its development and is being tested on humans for the first time.

Up to 24 Alzheimer's patients at the " mild to moderate " disease stage are to

be vaccinated, with the aim of this initial phase I trial being to

demonstrate the vaccine's safety and its suitability for human use.

The patients will be vaccinated four times over a period of three months,

and the safety and suitability of the vaccine will be analysed over six

months.

This development means that the EUR8.5 million venture capital finance

agreement the company concluded with Munich-based MIG-Fonds in April 2006

has reached a key milestone on schedule.

Affiris says it has developed the Alzheimer's vaccine from patented Affitope

technology, which is based on mimotopes and allows customized vaccines to be

manufactured cost-effectively.